Clinical Trials Browser

Phase 1 × NIH × oblimersen × Clear all

NCT00054548 2013-05-16

Combination Chemotherapy Plus Oblimersen in Treating Patients With Advanced Solid Tumors

Phase 1 Completed

Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

NCT00004862 2013-02-01

Augmerosen Plus Fludarabine and Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

Phase 1 Completed

LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00017251 2013-01-24

Combination Chemotherapy Plus Oblimersen in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer

Phase 1 Completed

Extensive Stage Small Cell Lung Cancer

NCT00039481 2013-01-17

Oblimersen Plus Combination Chemotherapy and Dexrazoxane in Treating Children and Adolescents With Relapsed or Refractory Solid Tumors

Phase 1 Completed

Cardiotoxicity

NCT00070083 2009-04-07

Oblimersen, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

Phase 1 Completed

Lymphoma, Lymphoma, Large B-Cell, Diffuse